H. Lundbeck A/S, an international pharmaceutical company, engages in the research, development, production, marketing, and sale of pharmaceuticals for the treatment of psychiatric and neurological disorders. Its products include Cipralex, Lexapro, Sipralexa, Sipralex, Cipramil, Seropram, Cipram, and Celexa for the treatment of depression, generalized anxiety disorder, panic disorder, and social anxiety disorder; Ebixa for the treatment of moderate to severe Alzheimer’s disease; Azilect for the treatment of Parkinson’s disease; Serdolect for the treatment of schizophrenia; and Deanxit for the treatment of mild depression. The company also offers Noritren, Nortrilen, Sensaval, Saroten, Sarotex, and Redomex for depression; and Cisordinol and Clopixol for treating schizophrenia and other psychotic disorders, anxiety, restlessness, and insomnia. In addition the company offers Cisordinol Depot, Clopixol Depot, Ciatyl-Z Depot, Fluanxol Depot, and Depixol for the maintenance and treatment of chronic psychotic disorders; and Cisordinol-Acutard, Clopixol-Acutard, Clopixol-Acuphase, and Ciatyl-Z-Acuphase for treating acute psychotic episodes and exacerbation of psychotic disorders. H. Lundbeck’s other products include Fluanxol, Fluanxol Mite, and Depixol for schizophrenia, other psychotic disorders, and mild depression; and Truxal and Truxaletten for the treatment of schizophrenia and other psychotic disorders, anxiety and restlessness, and withdrawal symptoms in drug addicts. The company also has various products under clinical development for the treatment of alcohol dependence, depression, mood disorders, schizophrenia and other psychotic disorders, sleep disorders, and stroke. H. Lundbeck operates primarily in Europe and the United States. The company has collaboration agreements with Solvay Pharmaceuticals B.V. and Wyeth; and a strategic alliance with Takeda Pharmaceutical Company Limited. The company was founded in 1915 and is headquartered in Copenhagen, Denmark.